The Science Spotlight series, authored by NBCC’s programs staff, analyzes recently published breast cancer research, the results of pivotal breast cancer clinical trials, and other newsworthy breast cancer data.
Recent Spotlights
Medicaid Expansion Associated with Fewer Breast Cancer Deaths
Access to quality health care saves lives—and new research demonstrates how crucial that access is for women with breast cancer.
Read moreChest-Wall Radiation after Mastectomy Offers No Survival Benefit at 10 Years
New research highlights the importance of studies that ask not only “what can we add?” but also “what can we safely remove?”
Read moreNew Data Show Lobular Breast Cancer Cases Are on the Rise
Cases of invasive lobular breast cancer are rising more than three times faster than breast cancer overall—a trend with distinct biology and unanswered questions.
Read moreRethinking Treatment for Low-Risk DCIS
Patients and their doctors now have evidence to support a choice that aligns with their values and priorities.
Read moreWhat New Research Says about Treatment De-Escalation
How do we minimize the harms of a cancer drug without minimizing the benefits?
Read moreThe Research on CDK4/6 Inhibitors
CDK4/6 inhibitors are reshaping treatment for HR+/HER2− breast cancer—but moving them into earlier settings raises hard questions about benefit, risk, and overtreatment.
Read moreFDA ODAC Meeting Considers Adequacy of Proposed Trial Design
An atypical FDA advisory meeting raised serious questions about trial design, evidence, and how cancer drugs get approved.
Read moreHER2-Low Breast Cancer and T-DXd
Do the benefits and toxicities of T-DXd warrant moving this therapy to early breast cancer?
Read moreAntibody Drug Conjugates and the DESTINY Trial
Antibody-drug conjugates promise to deliver toxic drugs specifically to cancer cells. The DESTINY trials show promise—and the limits of current survival data.
Read more